The Effect of Oligofructose-Enriched Inulin on Faecal Bacterial Counts and Microbiota-Associated Characteristics in Celiac Disease Children Following a Gluten-Free Diet: Results of a Randomized, Placebo-Controlled Trial

Natalia Drabińska 1, Elżbieta Jarocka-Cyorta 2, Lidia Hanna Markiewicz 3 and Urszula Krupa-Kozak 1,*

1 Department of Chemistry and Biodynamics of Food, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima 10 Str., 10-748 Olsztyn, Poland; n.drabinska@pan.olsztyn.pl
2 Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia & Mazury, Oczapowskiego 2 Str., 10-719 Olsztyn, Poland; e.jarocka@op.pl
3 Department of Immunology and Food Microbiology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima 10 Str., 10-748 Olsztyn, Poland; l.markiewicz@pan.olsztyn.pl
* Correspondence: u.krupa-kozak@pan.olsztyn.pl; Tel.: +48-89-523-46-18

Received: 15 January 2018; Accepted: 10 February 2018; Published: 12 February 2018

Abstract: Celiac disease (CD) is associated with intestinal microbiota alterations. The administration of prebiotics could be a promising method of restoring gut homeostasis in CD. The aim of this study was to evaluate the effect of prolonged oligofructose-enriched inulin (Synergy 1) administration on the characteristics and metabolism of intestinal microbiota in CD children following a gluten-free diet (GFD). Thirty-four paediatric CD patients (mean age 10 years; 62% females) on a GFD were randomized into two experimental groups receiving Synergy 1 (10 g/day) or placebo (maltodextrin; 7 g/day) for 3 months. The quantitative gut microbiota characteristics and short-chain fatty acids (SCFAs) concentration were analysed. In addition, side effects were monitored. Generally, the administration of Synergy 1 in a GFD did not cause any side effects. After the intervention period, Bifidobacterium count increased significantly (p < 0.05) in the Synergy 1 group. Moreover, an increase in faecal acetate and butyrate levels was observed in the prebiotic group. Consequently, total SCFA levels were 31% higher than at the baseline. The presented trial shows that Synergy 1 applied as a supplement of a GFD had a moderate effect on the qualitative characteristics of faecal microbiota, whereas it stimulated the bacterial metabolite production in CD children.

Keywords: celiac disease; inulin; prebiotic; gluten-free diet; gut microbiota; short-chain fatty acids

1. Introduction

Recent data emphasizes the pivotal role of microbiota homeostasis in maintaining the host’s health [1,2]. Commensal bacteria prevent the development of pathologic bacteria in the gut. Additionally, the intestinal microbiome is involved in the differentiation and proliferation of intestinal epithelial cells, the maintenance of gut integrity [1], the synthesis of vital nutrients, in particular vitamins (B-complex vitamins, vitamin K), the absorption of minerals (calcium, magnesium), and the fermentation of food. Therefore, a dysbiotic intestinal microbiota may contribute to the development of gastrointestinal, systemic, and metabolic diseases. It has been reported that disruptions in microbiota composition during infancy may contribute to autoimmune diseases, including celiac disease (CD) [3].

CD is one of the most common chronic and diet-related disorders, affecting approximately 1% of the global population [4]. In predisposed individuals, the ingestion of gluten-containing foods results...
in autoimmune enteropathy manifested by a variety of intestinal and extra-intestinal symptoms. The role of intestinal microbiota in CD aetiology is unclear, and it remains unknown whether microbiota dysbiosis is the cause or the consequence of CD [5]. Literature data have demonstrated disproportions between Gram-negative and Gram-positive bacteria and a lower number of beneficial strains (Bifidobacterium, Lactobacillus) in CD patients [6,7]. It has also been suggested that a gluten-free diet (GFD) itself can cause changes in the composition of intestinal bacteria [8,9]. In CD patients, microbiota dysbiosis continues to be observed even after long-term treatment with a GFD [6,10].

Microbiota evaluations can be performed in two ways: by analysing bacterial composition or by analysing bacterial activity [11]. Microbiota-associated characteristics (MAC) are defined as the features of the human body that are influenced by intestinal microbiota [11]. The most widely applied MAC in human studies is the analysis of the profile and concentration of faecal short-chain fatty acids (SCFAs) representing the unabsorbed fraction of SCFAs in the intestinal tract [12]. SCFAs are produced during the fermentation of carbohydrates by intestinal microbiota, and the main products are acetate, propionate, and butyrate. However, if the supply of carbohydrates is limited, the fermentation of other sources of energy, such as proteins and fats, occurs and results in the formation of branched-chain fatty acids (BCFAs) [13].

At present, there are no pharmacological agents against CD; therefore, a GFD is still the only available treatment for CD [14]. The importance of microbiota in CD pathogenesis has shifted the researchers’ focus to the modification of the composition and activity of intestinal microbiota. The administration of probiotics and prebiotics could be proposed as a relatively simple method of improving bacterial composition. The application of certain probiotic bacteria was shown to successfully restore the balance in microbiota composition of CD patients [15]. Prebiotics also confer many beneficial health effects [16], but unlike probiotics they are not living organisms but naturally occurring food components that are selectively utilized by the host microbiota. Among prebiotics, inulin-type fructans are the most widely studied, and are proven to increase Bifidobacterium and Lactobacillus counts in faecal samples [17]. Prebiotics have been successfully applied to restore the microbiota balance in patients suffering from inflammatory intestinal diseases [18,19], but to date they have not been evaluated in CD patients. Therefore, the aim of this study was to evaluate the effect of oligofructose-enriched inulin on the characteristics and activity of intestinal microbiota in CD children following a GFD.

2. Materials and Methods

2.1. Study Protocol

Thirty-four children (aged 4 to 18 years; 62% females) diagnosed with CD and following a GFD for at least 6 months were randomly allocated to a placebo (n = 16) or a Synergy 1 (n = 18) group, according to the study protocol described in detail by Krupa-Kozak et al. [20]. The demographic and anthropometric characteristics of patients have been presented previously [20]. During the 3-month intervention, children of the placebo group consumed maltodextrin (7 g orally/day; Maltodextrin DE 20, Hotrimex, Konin, Poland), whereas children of the Synergy 1 group consumed oligofructose-enriched inulin (10 g orally/day; Orafti® Synergy 1, Beneo, Tienen, Belgium) as a supplement of a GFD. Maltodextrin was selected as a placebo, as it is digested in the small intestine, contrary to prebiotics that reach the colon in intact form. Participants were asked to record the daily compliance with treatment as well as any adverse reactions occurring during the whole trial in the observation chart provided to each participant at the first visit. In addition, they filled out the authors’ original questionnaire concerning the last week of the study, which was aimed at assessing in detail any side-effects after the intake of supplement, such as discomfort, abdominal pain, and stool frequency and consistency. The last week was selected because the effect of the prebiotic was the most dominant at this stage of the study.
2.2. Ethics

The participants’ parents and caregivers signed written consent forms during the enrolment visit. The experimental design and all procedures have been approved by the Bioethics Committee of the Faculty of Medical Sciences of the University of Warmia and Mazury in Olsztyn (permission No. 23/2015 of 16 June 2015). Study visits were coordinated with regular visits held every 3 months in a gastroenterology clinic. The study was registered at ClinicalTrials database under the number NCT03064997 [21].

2.3. Samples Collection

The details of sample collection were presented in Krupa-Kozak et al. [20]. Briefly, faecal samples were collected from patients (at the baseline and at the end of experiment), transported to a laboratory on ice, and aliquoted separately for bacterial DNA isolation and SCFA analysis. For the genomic assay, approximately 100 mg of faeces was separated and stored at $-80^\circ$C. For the SCFA analysis, two aliquots of approximately 100 mg were weighted, and 150 µL of 10% formic acid was added to each sample as preservative before storage at $-80^\circ$C.

2.4. Isolation of Bacterial Genomic DNA

Immediately before DNA isolation, samples were defrosted at room temperature. For a quantitative analysis of microbial characteristics, genomic bacterial DNA was isolated from faecal samples using a commercial kit designated for human faecal specimens (GeneMATRIX Stool DNA Purification Kit, EURx, Gdańsk, Poland) according to the manufacturer’s protocol using the bead-beating method and a Gyrator UNIPREP 3D vortex (UniEquip, Planegg, Germany) as described in [22].

2.5. Quantitative Real-Time PCR

The quantitative characteristics of intestinal bacteria were determined by the real-time polymerase chain reaction (RT-PCR) technique with the use of group-specific primers according to the procedure described by Fotschki et al. [22] The DNA of predominant bacterial strains was used as a positive control and for the preparation of standard curves. Pure cultures of bacterial strains were cultivated as described by Fotschki et al. [22] and DNA was isolated with the same method as applied for faecal samples. Total bacterial counts and the counts of Bifidobacterium (BIF) and Lactobacillus (LAC) genera, the Bacteroides-Prevotella-Porphyromonas (BPP) group, and the Clostridium coccoides (Ccocc) and Clostridium leptum (Clept) groups were determined. Decimal dilutions of the DNA standard were used to plot a standard curve with each primer pair (Table 1). To be able to compare samples to the standards, the extracted DNA was not normalized to keep the same isolation efficiency and amplification conditions, allowing for the quantitative analysis. Amplifications were performed in the Quant Studio 6 Flex real-time PCR system (Thermo Fisher, Warsaw, Poland) in a total volume of 20 µL (10 µL of SYBR Green Jump-Start Taq ReadyMix (Sigma-Aldrich, Saint Louis, MO, USA), 1 µL of 10-fold diluted DNA, 200 µM of each primer, and PCR-grade water). The temperature program was as follows: 1 cycle at 95 °C for 2 min, 40 cycles at 95 °C for 15 s, primer annealing temperature (Table 1) for 1 min, and 72 °C for 30 s with signal acquisition. After each run, a melting curve was prepared to confirm the specificity of amplicons. The values were normalized according to the dilution and weight of the sample. The analyses were performed in duplicate, and final data were expressed as log10 of bacterial cells per gram of the sample on a wet weight basis.
Table 1. The primers used in the real-time polymerase chain reaction (RT-PCR) analysis.

| Target                      | Primer     | Sequence (5′ → 3′)                                      | T_a (°C) | Reference |
|-----------------------------|------------|--------------------------------------------------------|----------|-----------|
| Total bacteria              | UniF       | GTGSTGCAYGGYGYTGCGTCA ACGTCRTCCMCNCTTTCCT              | 60       | [23]      |
|                             | UniR       |                                                        |          |           |
| *Bifidobacterium*           | BIF-F      | TCGCG(T/C)GTTGGAAG CACATCCAGC(A/G)TCCAC                | 58       | [24]      |
|                             | BIF-R      | CCACATCCAGC(A/G)TCCAC                                  |          |           |
| *Clostridium leptum* group  | sg-Clept-F | GCACAAGCAGTGGA GTCTTCCCTTTCCTTCTTCCT                  | 53       | [25]      |
|                             | sg-Clept-R3| CTTCCTTCCGTTCCTTCTTCCTTCTTCCTTCTTCCT                 |          |           |
| *Bacteroides-Prevotella-Porphyromonas* | BPP-F   | GGTGTCGCGCTTAAGTCCAT CGGA(C/T)GTAAGGGCCGTCG          | 56       | [24]      |
|                             | BPP-R      | GGTGTCGCGCTTAAGTCCAT CGGA(C/T)GTAAGGGCCGTCG          |          |           |
| *Clostridium coccoides* group | g-ccoc-F  | AAATGACGGTACCTGACTAA CTTCGAGTTTCTATTCGCA              | 58       | [26]      |
|                             | g-ccoc-R   | AAATGACGGTACCTGACTAA CTTCGAGTTTCTATTCGCA              |          |           |
| *Lactobacillus*             | Lac1F      | AGCAGTAGGGAATCTCCTCA CACCGCTACACATGGAG               | 58       | [27]      |
|                             | Lab667     | AGCAGTAGGGAATCTCCTCA CACCGCTACACATGGAG               |          |           |

2.6. Microbiota-Associated Characteristics

Individual SCFAs in fecal samples were analysed by gas chromatography according to a modified method of Garcia-Villaba et al. [28]. Briefly, faecal samples of approximately 100 mg and 500 µL of a mixture of acetone and 0.03 M oxalic acid (3:2 ratio) were homogenized with a vortex for 1 min. Acetone was found to better extract SCFA than all of the solvents proposed by the authors [28]. Dilution with water gave unsatisfactory peak shapes; therefore, it was replaced by aqueous 0.03 M oxalic acid, which hardly improved peak shapes and allowed us to obtain higher levels of SCFA [29]. Then, samples were centrifuged for 20 min at 13,400 rpm, and the supernatants were collected into chromatography vials and introduced to the gas chromatography (GC) system.

The SCFAs were analysed in the Agilent 7890A gas chromatograph (Agilent, Wilmington, DE, USA) with a flame-ionization detector (FID) and the 7683B auto-injector. The compounds were separated in the SGE BP21 capillary column (SGE Analytical Science by Trajan, Ringwood, VIC, Australia; 30 m × 0.53 mm, film thickness: 0.5). The carrier gas was helium (Air Products and Chemicals, Allentown, PA, USA; 5 mL/min). The samples (0.5 µL) were injected in a split mode (10:1). The oven temperature was initially set at 85 °C, raised to 180 °C (6 °C/min), and maintained for 5 min. The injector temperature was 250 °C and the temperature of the flame ionization detector was 290 °C. External standards of acetic, propionic, butyric, isobutyric, valeric, and isovaleric acid were applied. The analyses were performed in triplicate.

2.7. Statistical Analysis

The results of the quantitative analyses of faecal microbiota and SCFAs are expressed as means ± standard error of the mean (SEM). The data collected from subjects with reported 80% intake were used in the final analysis (n = 25). Normal distribution of data was evaluated by the Shapiro–Wilk test. Student’s t-test or the Mann–Whitney U test was applied to compare differences between groups, as appropriate. Differences within groups before and after intervention were determined with the Student’s t-test or the Wilcoxon test, as appropriate. All statistical analyses were conducted using Statistica v. 12 software (StatSoft, Krakow, Polska). The significance of differences between the samples was determined at p < 0.05.

3. Results

3.1. Response to Intervention

In general, Synergy 1 was well-accepted by trial participants and did not cause discomfort. Based on three-months of observation, no specific side-effects were observed, except for single episodes of abdominal pain or diarrhoea that were noticed occasionally in both experimental groups. In one child
suffering from bloating and constipation before the enrolment, the alleviation of symptoms during the intake of Synergy 1 was noticed. The results of detailed observations of the last intervention week are summarised in Table 2. Mild abdominal pain lasting for two subsequent days was reported in three children, both in the Synergy 1 and placebo groups. The defecation frequency was similar in both experimental groups; however, the consistency of stool in children on a GFD supplemented with Synergy 1 was usually described as normal (95% of the time), while in the placebo group the consistency of stool was perceived as normal only 69% of the time. Two participants reported discomfort after taking the placebo that was described as moderate nausea.

| Observation                          | Synergy 1 | Placebo |
|--------------------------------------|-----------|---------|
| Abdominal pain                       | 3         | 3       |
| Everyday defecation (2) (%)          |           |         |
| Yes                                  | 90        | 81      |
| No                                   | 10        | 19      |
| Defecation No/day                    | 1.3 ± 0.5 | 1.1 ± 0.2 |
| Normal stool consistency (3) (%)     | 95        | 69      |
| Discomfort after the intake of supplement | 0          | 2       |

1 Number of episodes; 2 during 7-day evaluation period; 3 no diarrhea or constipation.

3.2. Quantitative Profile of Fecal Microbiota

The quantitative profiles of faecal microbiota of CD children are presented at Figure 1. The initial total bacteria number (TBN) as well as the initial counts of individual bacteria were similar in both experimental groups. A comparison of bacteria counts between the experimental groups after the three-month intervention revealed a significant increase \( p < 0.05 \) in BIF count in the Synergy 1 group. Moreover, the count of Clept in the Synergy 1 group was stable and at the end of experiment it was similar to the initial count, whereas in the placebo group the final Clept count was reduced. After the intervention, a decrease in the count of LAC was noticed in both experimental groups, but it was significant only in the Synergy 1 group. The determined alterations in the quantity of individual bacteria resulting from the intervention were reflected by the TBN, which remained constant in the Synergy 1 group, but tended to decrease in the placebo group.

![Figure 1. Quantitative characteristics of faecal microbiota before (T0) and after (T1) the intervention, expressed by means ± SEM (standard error of the mean) and by log cells/g of faeces. * \( p < 0.05 \). TBN: total bacterial counts; BIF: Bifidobacterium sp.; Clept: C. leptum; BPP: Bacteroides-Prevotella-Porphyromonas; Ccocc: Clostridium coccoides; LAC: Lactobacillus sp.](image-url)
3.3. Microbiota-Associated Characteristics

Based on the results of the gas chromatography analysis, acetic, propionic, and butyric acid were determined in dominant concentration in faecal samples of CD children (Table 3). Initially, the concentration of individual SCFAs was statistically similar in both experimental groups. After the experiment, a significant ($p < 0.05$) increase in faecal acetate and butyrate levels was observed in the group receiving Synergy 1; consequently, total SCFAs concentration was 31% higher than at the baseline. A comparison of both groups after the intervention revealed significantly ($p < 0.05$) higher levels of acetate and propionate in the Synergy 1 group. At the end of experiment, the faecal concentration of total SCFAs in the Synergy 1 group was significantly ($p < 0.05$) higher than in the placebo group.

The initial concentrations of total BCFAs, expressed as a sum of iso-butyric and iso-valeric acids, were similar in both experimental groups (Table 3). After the intervention, the relative concentration of BCFAs, expressed as the percentage of the total BCFAs in the total SCFAs, decreased by 31% in the Synergy 1 group but increased by 15% in the placebo group.

**Table 3.** Short chain fatty acids (SCFAs) concentration in faecal samples before (T0) and after (T1) the intervention, expressed by means ± SEM and by µmol/g of faeces.

| SCFA       | Placebo Group | Synergy 1 Group | Placebo: T0 vs. T1 $^2$ | Synergy 1: T0 vs. T1 $^2$ | T1: Placebo vs. Synergy 1 $^3$ |
|------------|---------------|-----------------|-------------------------|--------------------------|--------------------------------|
| Acetic     | 29.84 ± 1.93  | 28.82 ± 4.26    | 30.00 ± 3.35            | 44.06 ± 4.13             | 0.520                          |
| Propionic  | 9.91 ± 1.23   | 7.97 ± 1.55     | 10.16 ± 1.25            | 11.14 ± 0.61             | 0.692                          |
| iso-butyric| 1.41 ± 0.15   | 1.56 ± 0.33     | 1.60 ± 0.14             | 1.33 ± 0.13              | 0.678                          |
| Butyric    | 8.92 ± 1.37   | 8.21 ± 1.89     | 8.02 ± 1.27             | 10.41 ± 0.89             | 0.889                          |
| iso-valeric| 1.43 ± 0.18   | 1.46 ± 0.23     | 1.72 ± 0.19             | 1.56 ± 0.16              | 0.515                          |
| Valeric    | 1.55 ± 0.21   | 0.97 ± 0.16     | 1.72 ± 0.18             | 1.47 ± 0.18              | 0.030                          |
| Total SCFAs| 53.06 ± 5.52  | 48.99 ± 5.22    | 53.23 ± 6.94            | 69.95 ± 5.92             | 0.418                          |
| Total BCFAs| 2.84 ± 0.30   | 3.02 ± 0.40     | 3.32 ± 0.33             | 2.89 ± 0.28              | 0.765                          |
| Relative BCFAs $^1$| 5.35 | 6.16 | 6.24 | 4.13 |

$^*$ $p < 0.05$. $^1$ Relative concentration of the total branched-chain fatty acids (BCFAs) (sum of iso-butylic and iso-valeric acids) expressed as a percentage of the total SCFA. $^2$ Comparison between groups using Student’s t-test or the Mann–Whitney U test, as appropriate. $^3$ Comparison within groups before and after intervention using the Student’s t-test or the Wilcoxon test, as appropriate.

4. Discussion

Inulin-type fructans are one of the most widely researched groups of prebiotic compounds [30]. Their positive effect in counteracting intestinal microbiota dysbiosis has been demonstrated in human studies [31]. To the best of our knowledge, prebiotics have never been applied as a GFD supplement in CD patients. This study makes the first attempt to evaluate the effect of inulin-type fructans on gut microbiota characteristics and activity in CD children.

The first finding to emerge from the present study was an increase in the count of BIF in children following a GFD supplemented with Synergy 1. Our results are consistent with published studies where inulin-type fructans had a stimulating effect on BIF species regardless of the applied dose, degree of polymerization, or the duration of the experiment [32,33]. In CD patients, both adults and children, a decrease in the counts and diversity of BIF species have been reported [8]. Taking this into account, the obtained results are promising as they indicated that the administration of Synergy 1 in a GFD may counteract the reduction in BIF count in CD children. Much research has pointed out health-associated benefits of BIF and demonstrated the stimulation of immune response and suppression of pro-inflammatory cytokine synthesis [34–36]. However, it is important to highlight that changes in microbiota resulting from a dietary intervention with a prebiotic depend among other factors on the initial microbiota composition [37]. Tuohy et al. [38] observed a significant increase in BIF count in healthy volunteers receiving 8 g of inulin for two weeks, but a more prominent increase was observed in subjects with lower initial bacterial counts. After analysing the count of other bacteria groups, a constant quantity in Clept was observed in the experimental group supplemented
with Synergy 1, whereas a decreasing trend was observed in the placebo group. Clept is one of the predominant groups of gut bacteria, with a 16–25% share of the total bacteria [39], and includes Faecalibacterium prausnitzii and selected species of Eubacterium and Ruminococcus [40]. Clept plays a vital role in the intestine. It is involved in the fermentation of unabsorbed carbohydrates, which leads to the formation of butyric acid [41]. Changes in the composition and reduced counts of Clept group bacteria are characteristic of inflammatory intestinal diseases [42]. Dietary intervention with the prebiotic Synergy 1 resulted in a decrease in the final LAC count, which was an unforeseen result as based on literature data, inulin-type fructans were expected to stimulate the growth of LAC species [32]. In contrast, Adebola et al. [43] demonstrated that inulin did not stimulate any of the five probiotic strains of LAC, while other potential prebiotics, including lactulose and lactobionic acid, were utilized by bacteria and minimized the adverse effects of bile acid stress. The cited authors concluded that LAC have potentially stimulating effects only in specific formulations of probiotics and prebiotics [43].

A previous animal study on rats fed a GFD [44] showed that diets containing inulin reduced the faecal LAC count. Although oligofructose-enriched inulin applied as a supplement of a GFD had a rather moderate effect on changes in the qualitative characteristics of faecal microbiota of CD children, it impacted considerably the bacteria activity and altered the amount of bacterial metabolites. We noticed a remarkable increase in the total SCFAs concentration in the Synergy 1 group, mainly due to a significant increase in acetate concentration. This result could be attributed to an effective fermentation of inulin-type fructans administered in a GFD, which are a readily available source of energy for gut microbiota. Our findings are in agreement with previous studies reporting that diet and dietary compounds can modulate the metabolic activity of the intestinal microbiota rather than its quantitative and qualitative composition [45,46]. On the other hand, it could be expected that the acidification of the intestinal environment as a result of excessive SCFAs production could be associated with changes in bacteria composition, and potentially may promote the growth of beneficial microbiota simultaneously reducing the number of pathogenic species. In the present study, the increase in SCFAs amount was accompanied with the rise of BIF quantity. Protective BIF are considered to be the main producers of acetate [47]. Previously, acetic acid has been regarded as a pro-inflammatory trigger [48] but recent studies have demonstrated that acetate can prevent enteropathogenic infections [47]. The concentration of acetate acid is correlated with the expression of the Apoe, C3, and Pla2g2a genes, which are involved in the anti-inflammatory response [47]. Moreover, acetate prevents Escherichia coli O157-induced apoptosis of epithelial cells by decreasing transepithelial electrical resistance, and it is also involved in the reduction of intestinal permeability [47]. Acetate has been detected in the circulation at a concentration of 50–150 µM, which could point to a systemic mechanism of microbiota regulation [49]. The increase in acetic acid had the most dominant effect on the increase of total SCFAs. Consequently, the relative content of BCFAs was reduced after intervention, even though the concentration of BCFAs remained unchanged.

The concentrations of propionate and butyrate also increased in subjects supplemented with Synergy 1. The above could be attributed to the formula of Synergy 1, which is a mixture of short-chain fructooligosaccharides and long-chain inulin. Butyric acid is the main fermentation product of oligosaccharides, whereas inulin fermentation leads to the formation of propionic acid [50]. The importance of the increase in butyrate levels is associated with its role in the proliferation and differentiation of colon epithelial cells. Butyric acid regulates tight junction proteins and improves the integrity of the gut barrier by stimulating the expression of claudin-1 and zonula occludens-2, which participate in tight-junction assembly [13]. Butyric acid has also been shown to alleviate gastrointestinal mucosal inflammation [51].

5. Conclusions

In conclusion, the results of this study have demonstrated that the administration of oligofructose-enriched inulin is harmless and modulated the proportion of bacterial species in faecal
samples, increasing the counts of BIF in paediatric CD patients adhering to a GFD. However, the main findings were related to the shifting the faecal concentrations of bacterial metabolites provoked by prebiotic administration. In this study, the addition of Synergy 1 to a GFD of CD children modified the faecal SCFA profile, in particular increasing the concentration of acetate. This is the first-ever study to evaluate the effect of prebiotics on the gut microbiota of children with CD. Our findings indicate that GFD supplementation with Synergy 1 could be a promising therapeutic approach for modulating intestinal microbiota and their activity. Moreover, taking into account the critical role of intestinal microbiota in the development of several autoimmune diseases, such as type 1 diabetes [52], the application of prebiotics in a GFD may be helpful in the prevention of and protection against such possible complications. Admitting that the study reported herein has some limitations, in particular a small population size, inclusion of children with a wide age-range, and a relatively short intervention duration, the findings are interesting enough to encourage further well-powered intervention studies, which would provide sound data on the efficacy of prebiotic administration in the diet of CD patients.

Acknowledgments: We wish to thank sincerely all patients who participated in this study. The research was supported by statutory funds of the Department of Chemistry and Biodynamics of Food of the Institute of Animal Reproduction and Food Research, Polish Academy of Science (GW20).

Author Contributions: U.K.-K. conceived the study. U.K.-K., N.D. and E.J.-C. were involved in designing the study; N.D. and E.J.-C. carried out the study and collected samples; N.D. performed the main part of the experiments; I.H.M. performed the real-time PCR; U.K.-K. and N.D. analysed the data; N.D. drafted the manuscript, and U.K.-K., E.J.-C. and I.H.M. contributed to the further writing of the manuscript. All authors read and approved the final version of manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. O’Hara, A.M.; Shanahan, F. Gut Microbiota: Mining for Therapeutic Potential. *Clin. Gastroenterol. Hepatol.* 2007, 5, 274–284. [CrossRef] [PubMed]
2. Jandhyala, S.M.; Talukdar, R.; Subramanyam, C.; Vuyyuru, H.; Sasikala, M.; Reddy, D.N. Role of the normal gut microbiota. *World J. Gastroenterol.* 2015, 21, 8836–8847. [CrossRef] [PubMed]
3. Leonard, M.M.; Fasano, A. The microbiome as a possible target to prevent celiac disease. *Expert Rev. Gastroenterol. Hepatol.* 2016, 10, 555–556. [CrossRef] [PubMed]
4. Gujral, N.; Freeman, H.J.; Thomson, A.B.R. Celiac disease: Prevalence, diagnosis, pathogenesis and treatment. *World J. Gastroenterol.* 2012, 18, 6036–6059. [CrossRef] [PubMed]
5. Marasco, G.; di Biase, A.R.; Schiumerini, R.; Eusebi, L.H.; Ughi, R.; Raimondi, E.; Colecchia, A.; Festi, D. Gut microbiota and celiac disease. *Dig. Dis. Sci.* 2016, 61, 1461–1472. [CrossRef] [PubMed]
6. Di Cagno, R.; de Angelis, M.; De Pasquale, I.; Ndagijimana, M.; Vernocchi, P.; Piccioni, P.; Gagliardi, F.; Laghi, L.; Crecchio, C.; Guarneri, M.; et al. Duodenal and faecal microbiota of celiac children: Molecular, phenotype and metabolome characterization. *BMC Microbiol.* 2011, 11, 219. [CrossRef] [PubMed]
7. Nistal, E.; Caminero, A.; Vivas, S.; Ruiz de Morales, J.M.; Sáenz de Miera, L.E.; Rodríguez-Aparicio, L.B.; Casqueiro, J. Differences in faecal bacteria populations and faecal bacteria metabolism in healthy adults and celiac disease patients. *Biochimie* 2012, 94, 1724–1729. [CrossRef] [PubMed]
8. Sanz, Y.; Sánchez, E.; Marzotto, M.; Calabuig, M.; Torrini, S.; Dellaglio, F. Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. *FEMS Immunol. Med. Microbiol.* 2007, 51, 562–568. [CrossRef] [PubMed]
9. De Palma, G.; Nadal, I.; Medina, M.; Donat, E.; Ribes-Koníček, C.; Calabuig, M.; Sanz, Y. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. *BMC Microbiol.* 2010, 10, 63. [CrossRef] [PubMed]
10. Ilus, T.; Kaukinen, K.; Virta, I.J.; Pukkala, E.; Collin, P. Incidence of malignancies in diagnosed celiac patients: A population-based estimate. *Am. J. Gastroenterol.* 2014, 109, 1471–1477. [CrossRef] [PubMed]
11. Tjellström, B.; Stenhammar, L.; Högborg, L.; Fälth-Magnusson, K.; Magnusson, K.E.; Midtvedt, T.; Sundqvist, T.; Norin, E. Gut microflora associated characteristics in children with celiac disease. *Am. J. Gastroenterol.* 2005, 100, 2784–2788. [CrossRef] [PubMed]
12. Tjellström, B.; Stenhammar, L.; Sundqvist, T.; Fälth-Magnusson, K.; Hollén, E.; Magnusson, K.E.; Norin, E.; Midtvedt, T.; Högbom, L. The effects of oats on the function of gut microflora in children with coeliac disease. *Aliment. Pharmacol. Ther.* 2014, 39, 1156–1160. [CrossRef] [PubMed]

13. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* 2016, 7, 189–200. [CrossRef] [PubMed]

14. Leonard, M.M.; Sapone, A.; Catassi, C.; Fasano, A. Celiac disease and nonceliac gluten sensitivity: A review. *JAMA* 2017, 318, 647–656. [CrossRef] [PubMed]

15. Quagliariello, A.; Aloisi, I.; Bozziconici, N.; Luiselli, D.; D’Auria, G.; Martinez-Priego, L.; Pérez-Villarroya, D.; Langerholc, T.; Primec, M.; Mičetić-Turk, D.; et al. Effect of bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: A pilot study. *Nutrients* 2016, 8, 660. [CrossRef] [PubMed]

16. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat. Rev. Gastroenterol. Hepatol.* 2017. [CrossRef] [PubMed]

17. Wilson, B.; Whelan, K. Prebiotic inulin-type fructans and galacto-oligosaccharides: Definition, specificity, function, and application in gastrointestinal disorders. *J. Gastroenterol. Hepatol.* 2017, 32, 64–68. [CrossRef] [PubMed]

18. Wong, C.; Harris, P.; Ferguson, L. Potential benefits of dietary fibre intervention in inflammatory bowel disease. *Int. J. Mol. Sci.* 2016, 17, 919. [CrossRef] [PubMed]

19. Krupa-Kozak, U.; Drabinski, N.; Jarocka-Cyrta, E. The effect of oligofructose-enriched inulin supplementation on gut microbiota, nutritional status and gastrointestinal symptoms in paediatric coeliac disease patients on a gluten-free diet: Study protocol for a pilot randomized controlled trial. *Nutr. J.* 2017, 16. [CrossRef] [PubMed]

20. Wilson, B.; Whelan, K. Prebiotic inulin-type fructans and galacto-oligosaccharides: Definition, specificity, function, and application in gastrointestinal disorders. *J. Gastroenterol. Hepatol.* 2017, 32, 64–68. [CrossRef] [PubMed]

21. Wong, C.; Harris, P.; Ferguson, L. Potential benefits of dietary fibre intervention in inflammatory bowel disease. *Int. J. Mol. Sci.* 2016, 17, 919. [CrossRef] [PubMed]

22. Krupa-Kozak, U.; Drabinski, N.; Jarocka-Cyrta, E. The effect of oligofructose-enriched inulin supplementation on gut microbiota, nutritional status and gastrointestinal symptoms in paediatric coeliac disease patients on a gluten-free diet: Study protocol for a pilot randomized controlled trial. *Nutr. J.* 2017, 16. [CrossRef] [PubMed]

23. Fuller, Z.; Louis, P.; Mihajlovski, A.; Rungapamestry, V.; Ratcliffe, B.; Duncan, A.J. Influence of cabbage processing methods and prebiotic manipulation of colonic microflora on glucosinolate breakdown in man. *Br. J. Nutr.* 2007, 98, 364–372. [CrossRef] [PubMed]

24. Krupa-Kozak, U.; Drabinska, N.; Zieliinski, H.; Krupa-Kozak, U. Technological benefits of inulin-type fructans application in gluten-free products—A review. *Trends Food Sci. Technol.* 2016, 56. [CrossRef]
31. Salazar, N.; Dewulf, E.M.; Neyrinck, A.M.; Bindels, L.B.; Cani, P.D.; Mahillon, J.; de Vos, W.M.; Thissen, J.P.; Gueimonde, M.; de los Reyes-Gavilán, C.G.; et al. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. *Clin. Nutr.* 2015, 34, 501–507. [CrossRef] [PubMed]
32. Langlands, S.J. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. *Gut* 2004, 53, 1610–1616. [CrossRef] [PubMed]
33. Bouhnik, Y.; Raskine, L.; Champion, K.; Andrieux, C.; Penven, S.; Jacobs, H.; Simoneau, G. Prolonged administration of low-dose inulin stimulates the growth of bifidobacteria in humans. *Nutr. Res.* 2007, 27, 187–193. [CrossRef]
34. Aloisio, I.; Santini, C.; Biavati, B.; Dinelli, G.; Cencić, A.; Chingwaru, W.; Mogna, L.; Di Gioia, D. Characterization of *Bifidobacterium* spp. strains for the treatment of enteric disorders in newborns. *Appl. Microbiol. Biotechnol.* 2012, 96, 1561–1576. [CrossRef] [PubMed]
35. Klemenak, M.; Dolinšek, J.; Langerholc, T.; di Gioia, D.; Mićetić-Turk, D. Administration of *Bifidobacterium* breve decreases the production of TNF-α in children with celiac disease. *Dig. Dis. Sci.* 2015, 60, 3386–3392. [CrossRef]
36. Medina, M.; de Palma, G.; Ribes-Koninckx, C.; Calabuig, M.; Sanz, Y. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. *J. Inflamm.* 2008, 5, 19. [CrossRef]
37. Peterson, D.A.; McNulty, N.P.; Guruge, J.L.; Gordon, J.I. IgA response to symbiotic bacteria as a mediator of gut homeostasis. *Cell Host Microbe* 2007, 2, 328–339. [CrossRef] [PubMed]
38. Tuohy, K.M.; Finlay, R.K.; Wynne, A.G.; Gibson, G.R. A Human volunteer study on the prebiotic effects of HP-inulin—Faecal bacteria enumerated using fluorescent in situ hybridisation (FISH). *Anaerobe* 2001, 7, 113–118. [CrossRef]
39. Sghir, A.; Gramet, G.; Suau, A.; Rochet, V.; Pochart, P.; Dore, J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. *Appl. Environ. Microbiol.* 2000, 66, 2263–2266. [CrossRef] [PubMed]
40. Collins, M.D.; Lawson, P.A.; Willems, A.; Cordoba, J.J.; Fernandez-Garayzabal, J.; Garcia, P.; Cai, J.; Hippe, H.; Farrow, J.A. The phylogeny of the genus *Clostridium*: Proposal of five new genera and eleven new species combinations. *Int. J. Syst. Bacteriol.* 1994, 44, 812–826. [CrossRef] [PubMed]
41. Louis, P.; Flint, H.J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol. Lett.* 2009, 294, 1–8. [CrossRef] [PubMed]
42. Kabeerdoss, J.; Sankaran, V.; Pugazhendhi, S.; Ramakrishna, B.S. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: A case-control study in India. *BMC Gastroenterol.* 2013, 13, 20. [CrossRef] [PubMed]
43. Adebola, O.O.; Corcoran, O.; Morgan, W.A. Synbiotics: The impact of potential prebiotics inulin, lactulose and lactobionic acid on the survival and growth of lactobacilli probiotics. *J. Funct. Foods* 2014, 10, 75–84. [CrossRef]
44. Krupa-Kozak, U.; Markiewicz, L.H.; Lamparski, G.; Juśkiewicz, J. Administration of inulin-supplemented gluten-free diet modified calcium absorption and caecal microbiota in rats in a calcium-dependent manner. *Nutrients* 2017, 9. [CrossRef]
45. Beaumont, M.; Portune, K.J.; Steuer, N.; Lan, A.; Cerrudo, V.; Audebert, M.; Dumont, F.; Mancano, G.; Khodorova, N.; Andriamihaja, M.; et al. Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: A randomized, parallel, double-blind trial in overweight humans. *Am. J. Clin. Nutr.* 2017, 106, 1005–1019. [CrossRef] [PubMed]
46. Wu, G.D.; Compher, C.; Chen, E.Z.; Smith, S.A.; Shah, R.D.; Bittinger, K.; Chehoud, C.; Albenberg, L.G.; Nessel, L.; Gilroy, E.; et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. *Gut* 2016, 65, 63–72. [CrossRef] [PubMed]
47. Fukuda, S.; Toh, H.; Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping, D.L.; Suzuki, T.; et al. *Bifidobacteria* can protect from enteropathogenic infection through production of acetate. *Nature* 2011, 469, 543–547. [CrossRef] [PubMed]
48. Tjellström, B.; Högborg, L.; Stenhammars, L.; Filth-Magnusson, K.; Magnusson, K.; Norin, E.; Sundqvist, T.; Midtvedt, T. Faecal short-chain fatty acid pattern in childhood coeliac disease is normalised after more than one year’s gluten-free diet. *Microb. Ecol. Health Dis.* 2013, 24, 1–5. [CrossRef] [PubMed]
49. Richards, J.L.; Yap, Y.A.; McLeod, K.H.; Mackay, C.R.; Mariño, E. Dietary metabolites and the gut microbiota: An alternative approach to control inflammatory and autoimmune diseases. *Clin. Transl. Immunol.* **2016**, *5*, e82. [CrossRef] [PubMed]

50. Nilsson, U.; Nyman, M. Short-chain fatty acid formation in the hindgut of rats fed oligosaccharides varying in monomeric composition, degree of polymerisation and solubility. *Br. J. Nutr.* **2005**, *94*, 705. [CrossRef] [PubMed]

51. Kanauchi, O.; Andoh, A.; Iwanaga, T.; Fujiyama, Y.; Mitsuyama, K.; Toyonaga, A.; Bamba, T. Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model. *J. Gastroenterol. Hepatol.* **1999**, *14*, 1173–1179. [CrossRef] [PubMed]

52. Abela, A.-G.; Fava, S. Does the level of bacterial exposure in early life impact the risk of Type 1 diabetes? *Expert Rev. Clin. Immunol.* **2013**, *9*, 695–697. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).